In the BioHarmony Drug Report Database
Sitagliptin
Januvia, Ristaben, Tesavel, Xelevia (sitagliptin) is a small molecule pharmaceutical. Sitagliptin was first approved as Januvia on 2006-10-16. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. In addition, it is known to target dipeptidyl peptidase 4. Januvia’s patents are valid until 2026-11-24 (FDA).
Trade Name
|
Januvia, Ristaben, Tesavel, Xelevia |
|---|---|
Common Name
|
sitagliptin |
ChEMBL ID
|
CHEMBL1422 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Dipeptidyl aminopeptidase-IV inhibitors |
Image (chem structure or protein)